{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:18:56Z","timestamp":1792063136237,"version":"4.4.0"},"reference-count":59,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T00:00:00Z","timestamp":1312416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Minimal residual disease (MRD) has acquired a prominent role in the management of childhood and adult Acute Lymphoblastic Leukaemia (ALL) for its high prognostic value. Several studies have demonstrated the strong association between MRD and risk of relapse in childhood and adult ALL, irrespective of the methodology used. MRD is now used in clinical trials for risk assignment and to guide clinical management. Negativity at early time points may be considered to decrease treatment burden in patients who are likely to be cured with reduced intensity regimens. On the other hand, high MRD levels at late time points (end of consolidation) define ALL subgroups which deserve investigation of more effective treatments. The predictivity of MRD as a measurement of drug response <jats:italic>in vivo<\/jats:italic> opened new perspectives for its use in clinical decision, to deliver risk\u2010based treatments, and possibly as a surrogate for efficacy in the evaluation of novel therapeutic approaches.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08795.x","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T14:30:27Z","timestamp":1312468227000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"155","author":[{"given":"Giovanni","family":"Cazzaniga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gaipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Conter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1117"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402552"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.6065"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-185132"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8934"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4519"},{"key":"e_1_2_6_9_1","first-page":"1511a","article-title":"Impact of minimal residual disease (MRD) on prognosis in children with Philadelphia positive acute lymphoblastic leukemia (ALL) treated in the AIEOP\u2010BFM ALL 2000 study","volume":"112","author":"Biondi A.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20071"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000540"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(81)90002-3"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07350.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.010"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.7"},{"key":"e_1_2_6_18_1","first-page":"754a","article-title":"Early diagnosis and molecular\u2010based treatment of very highly resistant acute lymphoblastic leukemia in childhood","volume":"112","author":"Cario G.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-256131"},{"key":"e_1_2_6_20_1","first-page":"292","article-title":"Minimal residual disease as a surrogate marker for risk assignment to ALL patients","volume":"7","author":"Cazzaniga G.","year":"2003","journal-title":"Reviews in Clinical and Experimental Hematology"},{"key":"e_1_2_6_21_1","first-page":"271a","article-title":"Biological features and prognostic impact of CRLF2 overexpression in childhood ALL","volume":"116","author":"Cazzaniga G.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248146"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)10295-1"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0006"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400732"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1952"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20430"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06355-3"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.5"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-068478"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403559"},{"key":"e_1_2_6_33_1","doi-asserted-by":"crossref","first-page":"700a","DOI":"10.1182\/blood.V112.11.700.700","article-title":"Time point\u2010dependent concordance of flow cytometry and RQ\u2010PCR in the MRD Detection in childhood ALL: the experience of the AIEOP\u2010BFM\u2010 ALL MRD study group","volume":"112","author":"Gaipa G.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.308"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-082040"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07185.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-218560"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401279"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22550"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.227"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403683"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62002-8"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07941.x"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1414"},{"key":"e_1_2_6_46_1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood.V110.11.1425.1425","article-title":"Prognostic impact of minimal residual disease (MRD) in children is different in B or T lineage acute lymphoblastic leukemia: results of trial AIEOP\u2010BFM ALL 2000","volume":"110","author":"Schrappe M.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10965"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.12.1485"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253435"},{"key":"e_1_2_6_50_1","first-page":"1523","article-title":"Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia","volume":"9","author":"van Wering E.R.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02143.x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402922"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404535"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.17"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.275"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1746"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4386"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07377.x"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.7"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08795.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08795.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:57:46Z","timestamp":1697428666000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08795.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,4]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08795.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08795.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,4]]},"assertion":[{"value":"2011-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}